Clinical trials: Vulvar Cancer
Paget Disease, Extramammary
Topical 5% Imiquimod Cream for Vulvar Paget's Disease
The purpose of this study is to evaluate the efficacy, safety and immunological response of topical 5% imiquimod cream for non-invasive vulvar Paget's disease.
- Trial name
- NCT02385188
- Testing
- Imiquimod, paracetamol, lidocaine in Vaseline ointment
- Where
- 7 sites in Netherlands
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University Medical Center Nijmegen
Normal Vulval Skin, Lichen Sclerosus
Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease
Can vibrational spectroscopy be used to accurately assess vulval skin conditions? Vulval skin disorders are common and the diagnosis of these conditions can be difficult.
- Conditions
- Normal Vulval Skin, Lichen Sclerosus, High Grade Dysplasia - Usual Type ('VIN 2-3'), High Grade Dysplasia - Differentiated Type ('VIN 2-3')
- Trial name
- Vulval VS (NCT02223975)
- Where
- United Kingdom
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Gloucestershire Hospitals NHS Foundation Trust
Human Papillomavirus Infection
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
This study is to evaluate the safety and tolerability profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy women ages 18-45
- Trial name
- NCT05680454
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Neoplasms, Hiv
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
This study evaluates whether the Potlako+ intervention of community education, clinical provider support, and patient navigation can improve access to cancer case for patients presenting with symptoms of cancer.
- Conditions
- Neoplasms, Hiv, Cervical Cancer, Breast Cancer
- Trial name
- Potlako+ (NCT04141449)
- Testing
- Potlako intervention, Enhanced care
- Where
- Botswana
- Volunteers
- 874 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In…
- Trial name
- NCT00092521
- Testing
- V501, Human Papillomavirus (HPV) 16 Monovalent
- Volunteers
- 5,759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus, Cervical Cancer
Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention
The project aims to increase HPV vaccination and cervical cancer screening through a web-based mobile health education program called, Wheel of Wellness (WoW) and a brief negotiated interview (BNI).
- Conditions
- Human Papilloma Virus, Cervical Cancer, Human Papillomavirus Infection, Oropharyngeal Cancer
- Trial name
- NCT03346915
- Testing
- WoW and BNI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Protocol V503-021 is a long-term follow-up study of the V503-001 base study (NCT00543543) to evaluate the safety, immunogenicity, and long-term effectiveness of V503 vaccine in preventing cervical cancer and related precancers…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT02653118
- Testing
- V503, GARDASIL
- Volunteers
- 4,453 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus, Cervical Cancer
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
This study will examine the safety and tolerability of octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine formulated with amorphous aluminum hydroxysulfate (AAHS) and ISCOMATRIX™ (IMX).
- Conditions
- Human Papilloma Virus, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT00851643
- Testing
- Octavalent HPV with 15 mcg IMX / AAHS, Octavalent HPV with 30 mcg IMX / AAHS, Octavalent HPV with 60 mcg IMX / AAHS
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC